Upgrade to SI Premium - Free Trial

BofA Securities Upgrades Acadia Pharmaceuticals (ACAD) to Buy

March 25, 2026 6:05 AM
BofA Securities analyst Tazeen Ahmad upgraded Acadia Pharmaceuticals (NASDAQ: ACAD) from Neutral to Buy with a price target of $29.00.The ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Upgrades